These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1703 related items for PubMed ID: 15132713

  • 1. Cholinesterase inhibitors used in the treatment of Alzheimer's disease: the relationship between pharmacological effects and clinical efficacy.
    Wilkinson DG, Francis PT, Schwam E, Payne-Parrish J.
    Drugs Aging; 2004; 21(7):453-78. PubMed ID: 15132713
    [Abstract] [Full Text] [Related]

  • 2. Clinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors.
    Jann MW, Shirley KL, Small GW.
    Clin Pharmacokinet; 2002; 41(10):719-39. PubMed ID: 12162759
    [Abstract] [Full Text] [Related]

  • 3. Cholinesterase inhibitors for Alzheimer's disease.
    Birks J.
    Cochrane Database Syst Rev; 2006 Jan 25; 2006(1):CD005593. PubMed ID: 16437532
    [Abstract] [Full Text] [Related]

  • 4. Pharmacodynamic-tolerability relationships of cholinesterase inhibitors for Alzheimer's disease.
    Imbimbo BP.
    CNS Drugs; 2001 Jan 25; 15(5):375-90. PubMed ID: 11475943
    [Abstract] [Full Text] [Related]

  • 5. Cholinesterase inhibitors in the treatment of Alzheimer's disease: a comparison of tolerability and pharmacology.
    Nordberg A, Svensson AL.
    Drug Saf; 1998 Dec 25; 19(6):465-80. PubMed ID: 9880090
    [Abstract] [Full Text] [Related]

  • 6. Chronic treatment of old rats with donepezil or galantamine: effects on memory, hippocampal plasticity and nicotinic receptors.
    Barnes CA, Meltzer J, Houston F, Orr G, McGann K, Wenk GL.
    Neuroscience; 2000 Dec 25; 99(1):17-23. PubMed ID: 10924948
    [Abstract] [Full Text] [Related]

  • 7. Pharmacodynamic, pharmacokinetic and pharmacogenetic aspects of drugs used in the treatment of Alzheimer's disease.
    Noetzli M, Eap CB.
    Clin Pharmacokinet; 2013 Apr 25; 52(4):225-41. PubMed ID: 23408070
    [Abstract] [Full Text] [Related]

  • 8. The new cholinesterase inhibitors for Alzheimer's disease, Part 2: illustrating their mechanisms of action.
    Stahl SM.
    J Clin Psychiatry; 2000 Nov 25; 61(11):813-4. PubMed ID: 11105732
    [No Abstract] [Full Text] [Related]

  • 9. [Development of therapies for Alzheimer's disease based on cholinergic hypothesis-status quo and future directions].
    Shimohama S.
    Rinsho Shinkeigaku; 2013 Nov 25; 53(11):1036-8. PubMed ID: 24291871
    [Abstract] [Full Text] [Related]

  • 10. Nicotinic cholinergic modulation: galantamine as a prototype.
    Woodruff-Pak DS, Lander C, Geerts H.
    CNS Drug Rev; 2002 Nov 25; 8(4):405-26. PubMed ID: 12481195
    [Abstract] [Full Text] [Related]

  • 11. Unequal neuroprotection afforded by the acetylcholinesterase inhibitors galantamine, donepezil, and rivastigmine in SH-SY5Y neuroblastoma cells: role of nicotinic receptors.
    Arias E, Gallego-Sandín S, Villarroya M, García AG, López MG.
    J Pharmacol Exp Ther; 2005 Dec 25; 315(3):1346-53. PubMed ID: 16144975
    [Abstract] [Full Text] [Related]

  • 12. Enhancement of purinergic neurotransmission by galantamine and other acetylcholinesterase inhibitors in the rat vas deferens.
    Caricati-Neto A, D'angelo LC, Reuter H, Hyppolito Jurkiewicz N, Garcia AG, Jurkiewicz A.
    Eur J Pharmacol; 2004 Oct 25; 503(1-3):191-201. PubMed ID: 15496314
    [Abstract] [Full Text] [Related]

  • 13. The new cholinesterase inhibitors for Alzheimer's disease, Part 1: their similarities are different.
    Stahl SM.
    J Clin Psychiatry; 2000 Oct 25; 61(10):710-1. PubMed ID: 11078030
    [Abstract] [Full Text] [Related]

  • 14. Switching cholinesterase inhibitors in patients with Alzheimer's disease.
    Emre M.
    Int J Clin Pract Suppl; 2002 Jun 25; (127):64-72. PubMed ID: 12139369
    [Abstract] [Full Text] [Related]

  • 15. Acetylcholinesterase inhibition in Alzheimer's Disease.
    Ibach B, Haen E.
    Curr Pharm Des; 2004 Jun 25; 10(3):231-51. PubMed ID: 14754384
    [Abstract] [Full Text] [Related]

  • 16. An update on the pharmacology of galantamine.
    Villarroya M, García AG, Marco-Contelles J, López MG.
    Expert Opin Investig Drugs; 2007 Dec 25; 16(12):1987-98. PubMed ID: 18042006
    [Abstract] [Full Text] [Related]

  • 17. Pharmacology of selective acetylcholinesterase inhibitors: implications for use in Alzheimer's disease.
    Liston DR, Nielsen JA, Villalobos A, Chapin D, Jones SB, Hubbard ST, Shalaby IA, Ramirez A, Nason D, White WF.
    Eur J Pharmacol; 2004 Feb 13; 486(1):9-17. PubMed ID: 14751402
    [Abstract] [Full Text] [Related]

  • 18. Understanding and managing behavioural symptoms in Alzheimer's disease and related dementias: focus on rivastigmine.
    Robert P.
    Curr Med Res Opin; 2002 Feb 13; 18(3):156-71. PubMed ID: 12094826
    [Abstract] [Full Text] [Related]

  • 19. BCHE and CYP2D6 genetic variation in Alzheimer's disease patients treated with cholinesterase inhibitors.
    Chianella C, Gragnaniello D, Maisano Delser P, Visentini MF, Sette E, Tola MR, Barbujani G, Fuselli S.
    Eur J Clin Pharmacol; 2011 Nov 13; 67(11):1147-57. PubMed ID: 21630031
    [Abstract] [Full Text] [Related]

  • 20. Evidence that the clinical effects of cholinesterase inhibitors are related to potency and targeting of action.
    Poirier J.
    Int J Clin Pract Suppl; 2002 Jun 13; (127):6-19. PubMed ID: 12139368
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 86.